New drugs acquired via mergers, acquisitions or licensing agreements often come with an entourage of contract manufacturers. After several such transactions, you can find yourself surrounded by a tangle of CMOs. That’s problematic. Complex CMO networks are expensive and require many resources to manage. Plus, they prevent purchasing and operating at scale. Yet, the process of consolidating CMOs is daunting. Where do you begin?